Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
The two threads of intellectual property: identity and access
Merck’s patent fortress, a SCOTUS skinny label case, monopoly menus, and more
Voters Are Ahead of Politicians on Drug Pricing — And They Want Patent Reform
Year-in-review: How the USPTO was Hallowed Out in 2025
How the USPTO was Hollowed Out in 2025
New survey shows Americans want patent reform
Keytruda Qlex: Where’s the invention?
Two bipartisan bills target patent abuse
Still Overpatented, Still Overpriced
Merck’s Scheme to Product Hop Keytruda